Pancreatic Cancer Research

ResearcherYamagata UniversityActive in the last 2 years

Tomomi Sanomachi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1984-7741; OpenAlex author ID A5020065830. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 4

  1. Third-line S-1 or FOLFOX treatment in advanced pancreatic cancer who received gemcitabine+nab-paclitaxel and nanoliposomal-irinotecan+5-fluorouracil/leucovorin Co-author DOI 10.21203/rs.3.rs-5801148/v1↗
  2. Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis. Co-author DOI 10.1074/jbc.ra120.015223↗
  3. Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13667↗
  4. Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine. Co-author DOI 10.21873/anticanres.11227↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chifumi Kitanaka · 3 shared papers, 2016–2020 · strength 0.28
  2. Shuhei Suzuki · 3 shared papers, 2016–2020 · strength 0.28
  3. Susumu Hijioka · 1 shared paper, 2025 · strength 0.22
  4. Shin Yagi · 1 shared paper, 2025 · strength 0.22
  5. Akihiro Ohba · 1 shared paper, 2025 · strength 0.22
  6. Takuji Okusaka · 1 shared paper, 2025 · strength 0.22
  7. Chigusa Morizane · 1 shared paper, 2025 · strength 0.22
  8. Masahiro Yamamoto · 2 shared papers, 2019–2020 · strength 0.22
  9. Takashi Yoshioka · 2 shared papers, 2016–2019 · strength 0.16
  10. Atsushi Satō · 1 shared paper, 2020 · strength 0.12
  11. Hiroyuki Takeda · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.